Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CORT125281 + enzalutamide
- Development stage
- Unknown
- Lead developer
- Corcept Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**CORT125281 + enzalutamide** is an investigational combination therapy under clinical evaluation for **metastatic castration-resistant prostate cancer (mCRPC)**. CORT125281 (exicorilant) is a selective, competitive, and reversible antagonist of the **glucocorticoid receptor (GR)**, developed to block GR-mediated tumor escape mechanisms. Enzalutamide is a well-characterized **androgen receptor (AR) inhibitor** that disrupts androgen signaling, a driver of prostate cancer growth. The combination is being studied to assess whether co-targeting the GR and AR signaling pathways can overcome resistance to AR-directed therapies. Early studies indicate that the regimen is tolerated, with pharmacodynamic evidence for suppression of GR-regulated genes and anti-tumor activity. The developer/sponsor is **Corcept Therapeutics**[1][2][3].
- Brand names
- exicorilant
- Other names
- CORT-125281CORT125281CORT 12528114C-CORT125281exicorilantenzalutamide
02
Targets
GR (Glucocorticoid receptor)AR (Adrenergic receptors)
Beyond the preview
Go deeper on CORT125281 + enzalutamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CORT125281 + enzalutamide.